Ajanta Pharma Limited
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
What Ajanta files
- Others42
- Pledging41
- Investor Meet34
- Important12
- Board Meeting11
- Dividend/Bonus11
Ajanta Pharma allotted 23,400 fully paid-up equity shares of Rs. 2 each following option exercises. This increases the company's paid-up capital to Rs. 24.99 Cr, now comprising 12.49 Cr equity shares.
Ajanta Pharma's Paithan facility received a USFDA Establishment Inspection Report (EIR), with the inspection classified as Voluntary Action Indicated (VAI). This outcome supports continued operations for the US market.
Ajanta Pharma announced its 47th Annual General Meeting will be held virtually. The company will dispatch the Annual Report for FY25-26 and AGM notice. Details on shareholder voting eligibility will follow.
Ajanta Pharma's Board has approved the re-appointment of its Internal, Cost, and Tax Auditors for the upcoming financial year. This move ensures the company maintains robust financial oversight and compliance standards.
Ajanta Pharma's board approved granting 145,000 employee stock options, boosting staff incentives. Separately, 850 options were cancelled, returning to the ESOP pool. This impacts potential future share dilution.